In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

uniQure N.V.

http://www.uniqure.com

Latest From uniQure N.V.

Roche Shelves Phase III Huntington's Candidate Tominersen

Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.

Companies Clinical Trials

Bluebird Sickle Cell Gene Therapy Hangs In Balance

The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.” 

Commercial Gene Therapy

Roche Confident But Cautious On Alzheimer's Hopeful

The Swiss major has highlighted two high-risk, high-reward neurodegenerative programs that could be transformative for the treatment of Alzheimer's and Huntington's disease.

Neurology Clinical Trials

UniQure Expects To Resolve FDA Clinical Hold Within Three Months

The gene therapy EtranaDez for hemophilia B placed on clinical hold after a patient was diagnosed with liver cancer, but UniQure points to that patient’s extensive history of liver disease.

Gene Therapy Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Other Names / Subsidiaries
    • Amsterdam Molecular Therapeutics (AMT)
    • InoCard GmbH
    • uniQure Germany GmbH
    • uniQure U.S.A.
    • uniQure The Netherlands
    • uniQure Inc.
UsernamePublicRestriction

Register